Sanofi (NASDAQ:SNY) Shares Sold by First City Capital Management Inc.

First City Capital Management Inc. lowered its stake in shares of Sanofi (NASDAQ:SNY) by 29.8% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 13,970 shares of the company’s stock after selling 5,936 shares during the period. First City Capital Management Inc.’s holdings in Sanofi were worth $678,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Boston Partners boosted its holdings in Sanofi by 0.3% during the first quarter. Boston Partners now owns 13,066,403 shares of the company’s stock worth $635,280,000 after buying an additional 33,657 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after acquiring an additional 1,370,232 shares during the period. Barrow Hanley Mewhinney & Strauss LLC boosted its stake in shares of Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after acquiring an additional 3,164,092 shares in the last quarter. Mondrian Investment Partners LTD grew its position in shares of Sanofi by 43.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after acquiring an additional 1,190,141 shares during the period. Finally, Envestnet Asset Management Inc. increased its stake in shares of Sanofi by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after purchasing an additional 246,224 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SNY shares. StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Friday. Argus lifted their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Stock Performance

NASDAQ SNY opened at $57.63 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock’s 50 day simple moving average is $54.34 and its 200-day simple moving average is $50.48. The company has a market cap of $145.96 billion, a PE ratio of 28.96, a price-to-earnings-growth ratio of 1.62 and a beta of 0.60. Sanofi has a 1-year low of $42.63 and a 1-year high of $58.97.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.95 EPS. As a group, equities research analysts anticipate that Sanofi will post 4.25 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.